Illumina Wins FDA Authorization for Sequencing-Based COVID-19 Test
Illumina (NASDAQ: ILMN) announced Tuesday evening that the Food and Drug Administration had granted an Emergency Use Authorization (EUA) for COVIDSeq, a test that uses next-generation sequencing to detect SARS-CoV-2, the coronavirus that causes COVID-19.
The FDA has thus far issued more than 90 EUAs for in vitro diagnostic tests for COVID-19. But Illumina's COVIDSeq is the first COVID-19 diagnostic based on gene sequencing to receive such authorization.
Image source: Getty Images.
Source Fool.com
